CONTEXT: Without antiresorptive therapy, postmenopausal women lose bone mass after teriparatide (TPTD) discontinuation; estrogen treatment prevents bone loss in this setting. It is not known whether premenopausal women with regular menses lose bone mass after teriparatide discontinuation. OBJECTIVE: This study aimed to test the hypothesis that normally menstruating premenopausal women with idiopathic osteoporosis (IOP) will maintain teriparatide-associated bone mineral density (BMD) gains after medication cessation. DESIGN: Twenty-one premenopausal IOP women previously enrolled in an open-label pilot study of teriparatide (20 mcg for 18-24 mo), had substantial BMD increases at the lumbar spine (LS; 10.8 ± 8.3%), total hip (TH; 6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%). For this study, BMD was remeasured 2.0 ± 0.6 years after teriparatide cessation. PARTICIPANTS: Fifteen women, who had gained 11.1 ± 7.2% at LS and 6.1 ± 6.5% at TH and were premenopausal at teriparatide completion, were followed without antiresorptive treatment. RESULTS: Two years after completing teriparatide, BMD declined by 4.8 ± 4.3% (P = .0007) at the LS. In contrast, BMD remained stable at the femoral neck (-1.5 ± 4.2%) and TH (-1.1 ± 3.7%). Those who sustained LS bone loss >3% (-7.3 ± 2.9%; n = 10), did not differ from those with stable LS BMD (0.1 ± 1.1%; n=5) with regard to baseline body mass index, BMD at any site, or duration of followup, but were significantly older at re-evaluation (46 ± 3 vs 38 ± 7; P = .046), had larger increases in LS BMD during teriparatide treatment and higher cancellous bone remodeling on transiliac biopsy at baseline and completion of teriparatide treatment. Serum bone turnover markers did not differ at baseline or teriparatide completion, but tended to be higher at the re-evaluation timepoint in those with post-teriparatide bone loss. CONCLUSIONS: These findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone loss after teriparatide.
CONTEXT: Without antiresorptive therapy, postmenopausal women lose bone mass after teriparatide (TPTD) discontinuation; estrogen treatment prevents bone loss in this setting. It is not known whether premenopausal women with regular menses lose bone mass after teriparatide discontinuation. OBJECTIVE: This study aimed to test the hypothesis that normally menstruating premenopausal women with idiopathic osteoporosis (IOP) will maintain teriparatide-associated bone mineral density (BMD) gains after medication cessation. DESIGN: Twenty-one premenopausal IOP women previously enrolled in an open-label pilot study of teriparatide (20 mcg for 18-24 mo), had substantial BMD increases at the lumbar spine (LS; 10.8 ± 8.3%), total hip (TH; 6.2 ± 5.6%), and femoral neck (7.6 ± 3.4%). For this study, BMD was remeasured 2.0 ± 0.6 years after teriparatide cessation. PARTICIPANTS: Fifteen women, who had gained 11.1 ± 7.2% at LS and 6.1 ± 6.5% at TH and were premenopausal at teriparatide completion, were followed without antiresorptive treatment. RESULTS: Two years after completing teriparatide, BMD declined by 4.8 ± 4.3% (P = .0007) at the LS. In contrast, BMD remained stable at the femoral neck (-1.5 ± 4.2%) and TH (-1.1 ± 3.7%). Those who sustained LS bone loss >3% (-7.3 ± 2.9%; n = 10), did not differ from those with stable LS BMD (0.1 ± 1.1%; n=5) with regard to baseline body mass index, BMD at any site, or duration of followup, but were significantly older at re-evaluation (46 ± 3 vs 38 ± 7; P = .046), had larger increases in LS BMD during teriparatide treatment and higher cancellous bone remodeling on transiliac biopsy at baseline and completion of teriparatide treatment. Serum bone turnover markers did not differ at baseline or teriparatide completion, but tended to be higher at the re-evaluation timepoint in those with post-teriparatidebone loss. CONCLUSIONS: These findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone loss after teriparatide.
Authors: Adi Cohen; David W Dempster; Robert R Recker; Emily M Stein; Joan M Lappe; Hua Zhou; Andreas J Wirth; G Harry van Lenthe; Thomas Kohler; Alexander Zwahlen; Ralph Müller; Clifford J Rosen; Serge Cremers; Thomas L Nickolas; Donald J McMahon; Halley Rogers; Ronald B Staron; Jeanette LeMaster; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2011-08-10 Impact factor: 5.958
Authors: Kyle K Nishiyama; Adi Cohen; Polly Young; Ji Wang; Joan M Lappe; X Edward Guo; David W Dempster; Robert R Recker; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2014-03-31 Impact factor: 5.958
Authors: Dennis M Black; John P Bilezikian; Kristine E Ensrud; Susan L Greenspan; Lisa Palermo; Trisha Hue; Thomas F Lang; Joan A McGowan; Clifford J Rosen Journal: N Engl J Med Date: 2005-08-11 Impact factor: 91.245
Authors: Adi Cohen; Emily M Stein; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Serge Cremers; Donald J McMahon; Thomas L Nickolas; Ralph Müller; Alexander Zwahlen; Polly Young; Julie Stubby; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2013-03-29 Impact factor: 5.958
Authors: Adi Cohen; X Sherry Liu; Emily M Stein; Donald J McMahon; Halley F Rogers; Jeanette Lemaster; Robert R Recker; Joan M Lappe; X Edward Guo; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958
Authors: Richard Eastell; Thomas Nickelsen; Fernando Marin; Clare Barker; Peyman Hadji; Jordi Farrerons; Maurice Audran; Steven Boonen; Kim Brixen; Jose Melo Gomes; Barbara Obermayer-Pietsch; Avraam Avramidis; Gunnar Sigurdsson; Claus C Glüer Journal: J Bone Miner Res Date: 2009-04 Impact factor: 6.741
Authors: Adi Cohen; Thomas F Lang; Donald J McMahon; X Sherry Liu; X Edward Guo; Chiyuan Zhang; Emily M Stein; David W Dempster; Polly Young; Isra Saeed; Joan M Lappe; Robert R Recker; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2012-09-07 Impact factor: 5.958
Authors: David W Dempster; Juliet E Compston; Marc K Drezner; Francis H Glorieux; John A Kanis; Hartmut Malluche; Pierre J Meunier; Susan M Ott; Robert R Recker; A Michael Parfitt Journal: J Bone Miner Res Date: 2013-01 Impact factor: 6.741
Authors: Sanchita Agarwal; Elizabeth Shane; Thomas Lang; Stephanie Shiau; Mafo Kamanda-Kosseh; Mariana Bucovsky; Joan M Lappe; Julie Stubby; Robert R Recker; Yizhong Hu; Zexi Wang; X Edward Guo; Adi Cohen Journal: J Clin Endocrinol Metab Date: 2022-06-16 Impact factor: 6.134
Authors: Adi Cohen; Stephanie Shiau; Nandini Nair; Robert R Recker; Joan M Lappe; David W Dempster; Thomas L Nickolas; Hua Zhou; Sanchita Agarwal; Mafo Kamanda-Kosseh; Mariana Bucovsky; John M Williams; Donald J McMahon; Julie Stubby; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958